Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA-Dependent Protein Kinase

Elaine Willmore, BSc, PhD, Ana Skowronska, Evan A Mulligan, PhD, G. Ahmed, Sarah Elliott, PhD, Geoffrey P Summerfield, Karen Hamlen, Chris Lowe, Barbara W Durkacz, Tanja Stankovic

Blood (2010) 116 (21): 433.

https://doi.org/10.1182/blood.V116.21.433.433

Published: 2010

Journal Articles

Induction of a CD8 + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

Oliver Goodyear, Angelo Agathanggelou, Igor Novitzky-Basso, Shamyla Siddique, Tina McSkeane, Gordon Ryan, Paresh Vyas, Jamie Cavenagh, Tanja Stankovic, Paul Moss, Charles Craddock

Blood (2010) 116 (11): 1908–1918.

https://doi.org/10.1182/blood-2009-11-249474

Published: 2010

Includes: Supplemental data

Journal Articles

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

Giles Best, PhD, Anne Gardiner, BSc, Rachel Ibbotson, PhD, Aneela Majid, PhD, Renata Walewska, MD, Belinda Austen, MD, Tanja Stankovic, PhD, Martin Dyer, MD, David Graham Oscier, MD

Blood (2006) 108 (11): 2795.

https://doi.org/10.1182/blood.V108.11.2795.2795

Published: 2006

Journal Articles

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

Victoria Weston, PhD, Claire Baker, BSc, Belinda Austen, BMBCh, Malcolm Taylor, PhD, Paul Moss, PhD, Tanja Stankovic, PhD

Blood (2006) 108 (11): 2110.

https://doi.org/10.1182/blood.V108.11.2110.2110

Published: 2006

Journal Articles

CLL Tumours with a Deletion of 11q Form Two Functional Subgroups Based on the Mutation Status of the Remaining ATM Allele.

Belinda Austen, Maria Podinovskaia, Claire Almond, Graham Fews, Anne Gardiner, David Oscier, Paul Moss, Tanja Stankovic

Blood (2005) 106 (11): 710.

https://doi.org/10.1182/blood.V106.11.710.710

Published: 2005

Journal Articles

Identification of ATM Mutations in Multiple Myeloma Tumours.

Belinda Austen, BMBCH, Maria Podinovskaia, BSc, Jane Starcynski, PhD, Giancarlo Barone, BSc, Anne Reiman, BM, Phil Byrd, PhD, Guy Pratt, PhD, Malcolm Taylor, PhD, Tanja Stankovic, PhD

Blood (2005) 106 (11): 1562.

https://doi.org/10.1182/blood.V106.11.1562.1562

Published: 2005

Journal Articles

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Belinda Austen, MRCP, Christopher Fegan, MD, MRCP, MRCPath, Paul Moss, Phd,MRCP,MRCPath, Tanja Stankovic, Phd

Blood (2004) 104 (11): 774.

https://doi.org/10.1182/blood.V104.11.774.774

Published: 2004

NARROW

ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA-Dependent Protein Kinase

Induction of a CD8 + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

CLL Tumours with a Deletion of 11q Form Two Functional Subgroups Based on the Mutation Status of the Remaining ATM Allele.

Identification of ATM Mutations in Multiple Myeloma Tumours.

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Email alerts

ASH Publications

American Society of Hematology

ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA-Dependent Protein Kinase

Induction of a CD8 + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

CLL Tumours with a Deletion of 11q Form Two Functional Subgroups Based on the Mutation Status of the Remaining ATM Allele.

Identification of ATM Mutations in Multiple Myeloma Tumours.

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only